建立人類非小型細胞肺癌之癌幹細胞對藥物的篩選平台

Abstract

本實驗以肺癌類幹細胞為模式研究 teroxirone 與中草藥抑制細胞生長的效果。之前研究已經知道低劑量的 teroxirone 具有抑制人類非小細胞肺癌 (NSCLC) 細胞生長之效果，在這次實驗中利用 BrdU assay 、反轉錄聚合酶連鎖反應、西方墨點法及 TUNEL assay 證實此藥物會藉由引起細胞凋亡而抑制 NSCLC 細胞之癌類幹細胞的生長，並且會抑制幹細胞標記分子的表現。另一部分，已經有報告指出多種中草藥具有抗癌效力，而本實驗篩選出中草藥 A 可以抑制 H1975 (EGFR 雙重突變的肺癌細胞株) 貼附型細胞及癌類幹細胞的生長，利用流式細胞儀、反轉錄聚合酶連鎖反應及西方墨點法證實此中藥會誘使 H1975 細胞凋亡，並且也會抑制幹細胞標記分子的表現。This study is based on the lung cancer stem-like cells model, which may be higher metastasis and resistance. To identify teroxirone and Chinese medicine herbs (CMH) that can potentially eradicate lung cancer stem-like cells, we will confirm the platform of lung cancer stem-like cells established. Previous report showed that teroxirone inhibited growth of human non-small-cell-lung-cancer cells (NSCLC) at low concentrations. Using BrdU assay, RT-PCR, western blot and TUNEL assay, this study showed that the drug reduced the cells proliferation by apoptosis and inhibited expression of the related stemness markers. The next part, Some recent studies showed that many CMHs possessed effects of anticancer. This study showed that CMH A inhibits growth of H1975 (mutant EGFR-L858R/T790M) monolayer and spheroid cells. Using flow cytometry, RT-PCR and western blot, this study confirmed that this CMH induced apoptosis and inhibited expression of the related stemness markers in H1975 cells.